Dear Investors and Friends of Cascade Prodrug Inc,
On behalf of our leadership team, I am pleased to inform you that the FDA has granted the company Orphan Drug Designation [ODD] for CPD 100Li for the treatment of pancreatic cancer.
At a high level this designation provides:
- Tax credits up to 50% for research and clinical drug testing expenses
- Eligibility for market exclusivity for 7 years AFTER pre-market approval
- Waiver of new drug application [NDA] application fee [Approximately worth $2M+]
- Pediatric Research Equity Act Exemption
In summary, this designation on the part of the FDA clearly supports the direction and focus the company is pursuing under its preclinical development and commercial partnering initiatives.
We thank our investors and friends for their support.
Co-Founder and Managing Director
Cascade Prodrug, Inc.